novo nordisk glp 1 drug Ozempic is first GLP-1 FDA-approved for kidney disease Novo's Wegovy becomes first GLP-1
Description
Other ocular Issues
The once-weekly injection and 15.3% mean body weight reduction from STEP-1 trials established Wegovy as the anti-obesity medication clinical benchmark
Urgent medical attention is required for sudden vision loss, numerous new floaters, flashes of light, or a curtain across the visual field
Vitale, M., Haxhi, J., Cirrito, T
How is oral semaglutide taken
Nauck M
